Development and characterization of an in vitro release assay for liposomal ciprofloxacin for inhalation

Journal of Pharmaceutical Sciences

Volumn 103, Issue 1, 2014, Pages 314-327

  Cipolla, David ^a,b   Wu, Huiying ^b   Eastman, Simon ^c   Redelmeier, Tom ^c   Gonda, Igor ^b   Chan, Hak Kim ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ARADIGM CORPORATION   (United States)

^c Northern Lipids Inc   (Canada)

Author keywords

ciprofloxacin; controlled release; dissolution; in vitro release; liposomes; nanoparticles; pulmonary drug delivery

Indexed keywords

CIPROFLOXACIN; LIPOQUIN; LIPOSOME; NANOPARTICLE; PULMAQUIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED DRUG RELEASE; DRUG DETERMINATION; DRUG FORMULATION; DRUG SOLUBILITY; IN VITRO STUDY;

EID: 84890527843     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23795     Document Type: Article

References (33)

1. Cipolla D, Redelmeier T, Eastman S, Bruinenberg P, Gonda I,. 2011. Liposomes, niosomes and proniosomes-a critical update of their (commercial) development as inhaled products. In Respiratory Drug Delivery Europe 2011;, Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, Eds. River Grove, Illinois: Davis Healthcare Int'l Publishing, pp 41-54.
2. Cipolla D, Gonda I, Chan HK,. 2013. Liposomal formulations for inhalation. Ther Deliv 4: 1047-1072.
3. Cipolla D, Chan HK,. 2013. Inhaled antibiotics to treat lung infection. Pharm Pat Analyst 2: 647-663.
4. Serisier DJ,. 2012. Inhaled antibiotics for lower respiratory tract infections: Focus on ciprofloxacin. Drugs Today 48: 339-351.
5. Serisier DJ, Bilton D, De Soyza A, Thompson PJ, Kolbe J, Greville HW, Cipolla D, Bruinenberg P, Gonda I,. 2013. Inhaled, dual-release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2)-A randomised, double-blind, placebo-controlled trial. Thorax 68 (9): 812-817.
6. Martinez M, Rathbone M, Burgess D, Huynh M,. 2008. In vitro and in vivo considerations associated with parenteral sustained release products: A review based upon information presented and points expressed at the 2007 controlled release society annual meeting. J Control Release 129: 79-87.
7. Cipolla D, Wu H, Chan J, Chan HK, Gonda I,. 2013. Liposomal ciprofloxacin for inhalation retains integrity following nebulization. In Respiratory Drug Delivery Europe 2013;, Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, Eds. Berlin, Germany: Davis Healthcare Int'l Publishing, pp 237-242.
8. Brown CK, Friedel HD, Barker AR, Buhse LF, Keitel S, Cecil TL, Kraemer J, Morris M, Reppas C, Stickelmeyer MP, Yomota C, Shah VP,. 2011. FIP/AAPS joint workshop report: Dissolution/In vitro release testing of novel/special dosage forms. AAPS Pharm Sci Tech 12: 782-94.
9. US FDA CDER Draft Guidance: Liposome Drug Products. 2002. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm070570.pdf. Accessed November 14, 2013.
10. Allen TM, Cleland LG,. 1980. Serum-induced leakage of liposome contents. Biochim Biophys Acta 597: 418-426.
11. Weinstein JN, Klausner RD, Innerarity T, Ralston E, Blumenthal R,. 1981. Phase transition release, a new approach to the interaction of proteins with lipid vesicles. Applications to lipoproteins. Biochim Biophys Acta 647: 270-284.
12. Haran G, Cohen R, Bar LK, Barenholz Y,. 1993. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1151: 201-215.
13. Lasic DD, Ceh B, Stuart MCA, Guo L, Frederik PM, Barenholz Y,. 1995. Transmembrane gradient driven phase transitions within vesicles: Lessons for drug delivery. Biochim Biophys Acta 1239: 145-156.
14. Hunt CA,. 1982. Liposomes disposition in vivo: Liposome stability in plasma and implications for drug carrier function. Biochim Biophys Acta 719: 450-463.
15. Bhardwaj U, Burgess DJ,. 2010. A novel USP apparatus 4 based release testing method for dispersed systems. Int J Pharm 388: 287-294.
16. Xu X, Khan MA, Burgess DJ,. 2012. A two-stage reverse dialysis in vitro dissolution testing method for passive targeted liposomes. Int J Pharm 426: 211-218.
17. Terzano C, Allegra L, Alhaique F, Marianecci C, Carafa M,. 2005. Non-phospholipid vesicles for pulmonary glucocorticoid delivery. Eur J Pharm Biopharm 59: 57-62.
18. Scherphof G, Roerdink F, Waite M, Parks J,. 1978. Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins. Biochim Biophys Acta 542: 296-307.
19. Storm G, van Bloois L, Brouwer M, Crommelin DJ,. 1985. The interaction of cytostatic drugs with adsorbents in aqueous media. The potential implications for liposome preparation. Biochim Biophys Acta 10: 343-351.
20. Ong HX, Benaouda F, Traini D, Cipolla D, Gonda I, Forbes B, Young PM,. 2013. In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation. Eur J Pharm Biopharm [Epub ahead of print.].
21. Webb MS, Boman NL, Wiseman DJ, Saxon D, Sutton K, Wong KF, Logan P, Hope MJ,. 1998. Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulation. Antimicrob Agents Chemother 42: 45-52.
22. Yim D, Blanchard JD, Mudumba S, Eastman S, Manda K, Redelmeier T, Farr SJ,. 2006. The development of inhaled liposome-encapsulated ciprofloxacin to treat cystic fibrosis. In Respiratory Drug Delivery 2006;, Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, Eds. River Grove, Illinois: Davis Healthcare Int'l Publishing, pp 425-428.
23. Cipolla D, Dayton F, Fulzele SV, Gabatan E, Mudumba S, Wu H, Yim D, Zwolinski R,. 2010. Inhaled liposomal ciprofloxacin: In vitro properties and aerosol performance. In Respiratory Drug Delivery 2010;, Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, Young PM, Eds. River Grove, Illinois: Davis Healthcare Int'l Publishing, pp 409-414.
24. Schreier H, Gonzalez-Rothi RJ, Stecenko AA,. 1993. Pulmonary delivery of liposomes. J Control Release 24: 209-223.
25. Allen TM., 1981. A study of phospholipid interactions between high-density lipoproteins and small unilamellar vesicles. Biochim Biophys Acta 640: 385-397.
26. Forte TM, Cross CE, Gunther RA, Kramer GC,. 1983. Characterization of sheep lung lymph lipoproteins: Chemical and physical properties. J Lipid Res 24: 1358-1367.
27. Marques MRC, Loebenberg R, Almukainzi M,. 2011. Simulated biological fluids wih possible application in dissolution testing. Dissolut Technol 18: 14-28.
28. Lieb WR, Stein WD,. 1971. Implications for two different types of diffusion for biological membranes. Nat New Biol 234: 220-222.
29. Lichtenberg D, Robson RJ, Dennis EA,. 1983. Solubilization of phospholipids by detergents. Structural and kinetic aspects. Biochim Biophys Acta 737: 285-304.
30. Liu Y, Regen SL,. 1993. Control over vesicle rupture and leakage by membrane packing and by the aggregation state of an attacking surfactant. J Am Chem Soc 115: 708-713.
31. Bruinenberg P, Otulana B, Blanchard J, Cipolla D, Wilson J, Serisier D,. 2009. Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis (CF) patients. 32nd European Cystic Fibrosis Conference, Brest, France. J Cystic Fibrosis 8 (Suppl 2), S49.
32. Bruinenberg P, Blanchard J, Cipolla D, Serisier D,. 2010. Safety, tolerability and pharmacokinetics of novel liposomal ciprofloxacin formulations for inhalation in healthy volunteers and in non-cystic bronchiectasis patients. American Thoracic Society (ATS) International Conference, New Orleans, LA. Am J Respir Crit Care Med 181: A3192.
33. Cipolla D, Gonda I, Serisier D, Bruinenberg P,. 2011. Dual Release Ciprofloxacin for Inhalation (DRCFI) improves time to first exacerbation in Bronchiectasis. International Society of Aerosols in Medicine 2011 Congress, Rotterdam, Netherlands, Poster P-014, pg. A-27, JAMPPD, Vol. 24, Number 3, 2011.